Study Title
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies (NCT02485119)
Trial Description
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors. The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity. This trial is sponsored by Bayer. [1]
Study Data
- Condition: Neoplasms
- Interventions:
- Drugs used in this trial
- BAY94-9343
- Drugs used in this trial
- Phase: I
- Estimated Enrollment: 15
- Start: August 2015
- Estimated Completion: November 2017
- Last verified: June 2015
Study Schematic
(Coming soon)
Click here to Return to Drug map
Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
